Keyphrases
Glioblastoma
61%
Polycystic Ovary Syndrome
60%
Metformin
60%
Tumor
42%
Chemotherapy
37%
Meta-analysis
34%
Hypofibrinolysis
32%
Necrosis
32%
Brain Tumor
32%
Confidence Interval
31%
Neutrophils
31%
Systematic Meta-analysis
30%
Insulin Resistance
26%
Thrombophilia
26%
Progression-free Survival
25%
Radiation Therapy
22%
Body Mass Index
21%
Isocitrate Dehydrogenase 1 (IDH1)
20%
Coronary Risk Factors
18%
Plasminogen Activator inhibitor-1 (PAI-1)
18%
Brain Metastases
18%
Factor V Leiden mutation
18%
Inhibitor Activity
18%
Medical Literature
18%
Tumor Cells
17%
Headache
17%
Glioma Model
17%
Overall Survival
17%
Statins
17%
Ferroptosis
17%
Tumor Necrosis
17%
Cell Death
17%
Bevacizumab
16%
Murine Model
16%
Weight Loss
16%
Glioblastoma Progression
16%
Loss Reduction
15%
Long-term Survival
15%
Hyperinsulinemia
15%
Delayed Complication
15%
Radiographic Study
15%
Etiology
15%
Cerebrospinal Fluid Biomarkers
15%
Appropriate Treatment
15%
Spinal Metastasis
15%
Irradiation
15%
Cancer Treatment
15%
LDL Cholesterol
15%
Phase II Trial
15%
Cyclin-dependent Kinase 4 (CDK4)
15%
Medicine and Dentistry
Glioblastoma
100%
Polycystic Ovary Syndrome
75%
Glycon
60%
Neoplasm
37%
Cancer
30%
Progression Free Survival
30%
Idiopathic Intracranial Hypertension
30%
Thrombophilia
30%
Systematic Review
30%
Ganglioglioma
28%
Necrosis
26%
Insulin Resistance
26%
Overall Survival
24%
Surgery
24%
Body Mass Index
22%
Radiation Therapy
20%
Magnetic Resonance Imaging
20%
Plasminogen Activator Inhibitor
20%
Cerebrospinal Fluid
18%
Ischemic Heart Disease
18%
Biological Marker
18%
Meta-Analysis
17%
Headache
17%
Tumor Necrosis
17%
Combination Therapy
16%
Neutrophil
16%
Long Term Survival
15%
Menstruation
15%
Hyperinsulinemia
15%
Visual Field
15%
Strongyloidiasis
15%
Spinal Cord Metastasis
15%
Bevacizumab
15%
Acute Lymphoblastic Leukemia
15%
Cancer Stem Cell
15%
Peripheral Nerve
15%
Papilledema
15%
Isocitrate Dehydrogenase
15%
Neuro-Oncology
15%
Cancer Treatment
15%
Alisertib
15%
Histology
15%
Positron Emission Tomography
15%
Ependymoma
15%
Tamoxifen
15%
Gigantism
15%
Phase II Trials
15%